C Hasenoehrl1, U Taschler1, M Storr2,3, R Schicho1. 1. Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria. 2. Department of Medicine, Ludwig-Maximilians University, Munich, Germany. 3. Zentrum für Endoskopie, Starnberg, Germany.
Abstract
BACKGROUND: In ancient medicine, extracts of the marijuana plant Cannabis sativa were used against diseases of the gastrointestinal (GI) tract. Today, our knowledge of the ingredients of the Cannabis plant has remarkably advanced enabling us to use a variety of herbal and synthetic cannabinoid (CB) compounds to study the endocannabinoid system (ECS), a physiologic entity that controls tissue homeostasis with the help of endogenously produced CBs and their receptors. After many anecdotal reports suggested beneficial effects of Cannabis in GI disorders, it was not surprising to discover that the GI tract accommodates and expresses all the components of the ECS. Cannabinoid receptors and their endogenous ligands, the endocannabinoids, participate in the regulation of GI motility, secretion, and the maintenance of the epithelial barrier integrity. In addition, other receptors, such as the transient receptor potential cation channel subfamily V member 1 (TRPV1), the peroxisome proliferator-activated receptor alpha (PPARα) and the G-protein coupled receptor 55 (GPR55), are important participants in the actions of CBs in the gut and critically determine the course of bowel inflammation and colon cancer. PURPOSE: The following review summarizes important and recent findings on the role of CB receptors and their ligands in the GI tract with emphasis on GI disorders, such as irritable bowel syndrome, inflammatory bowel disease, and colon cancer.
BACKGROUND: In ancient medicine, extracts of the marijuana plant Cannabis sativa were used against diseases of the gastrointestinal (GI) tract. Today, our knowledge of the ingredients of the Cannabis plant has remarkably advanced enabling us to use a variety of herbal and synthetic cannabinoid (CB) compounds to study the endocannabinoid system (ECS), a physiologic entity that controls tissue homeostasis with the help of endogenously produced CBs and their receptors. After many anecdotal reports suggested beneficial effects of Cannabis in GI disorders, it was not surprising to discover that the GI tract accommodates and expresses all the components of the ECS. Cannabinoid receptors and their endogenous ligands, the endocannabinoids, participate in the regulation of GI motility, secretion, and the maintenance of the epithelial barrier integrity. In addition, other receptors, such as the transient receptor potential cation channel subfamily V member 1 (TRPV1), the peroxisome proliferator-activated receptor alpha (PPARα) and the G-protein coupled receptor 55 (GPR55), are important participants in the actions of CBs in the gut and critically determine the course of bowel inflammation and colon cancer. PURPOSE: The following review summarizes important and recent findings on the role of CB receptors and their ligands in the GI tract with emphasis on GI disorders, such as irritable bowel syndrome, inflammatory bowel disease, and colon cancer.
Authors: L Manara; T Croci; F Guagnini; M Rinaldi-Carmona; J P Maffrand; G Le Fur; S Mukenge; G Ferla Journal: Dig Liver Dis Date: 2002-04 Impact factor: 4.088
Authors: E M Rock; D Bolognini; C L Limebeer; M G Cascio; S Anavi-Goffer; P J Fletcher; R Mechoulam; R G Pertwee; L A Parker Journal: Br J Pharmacol Date: 2012-04 Impact factor: 8.739
Authors: F Guagnini; M Valenti; S Mukenge; I Matias; A Bianchetti; S Di Palo; G Ferla; V Di Marzo; T Croci Journal: Gut Date: 2006-01-19 Impact factor: 23.059
Authors: Cheryl L Limebeer; Erin M Rock; Nirushan Puvanenthirarajah; Micah J Niphakis; Benjamin F Cravatt; Linda A Parker Journal: Behav Neurosci Date: 2016-04 Impact factor: 1.912
Authors: Jakub Fichna; Jodianne T Wood; Malvina Papanastasiou; Subramanian K Vadivel; Piotr Oprocha; Maciej Sałaga; Marta Sobczak; Anna Mokrowiecka; Adam I Cygankiewicz; Piotr K Zakrzewski; Ewa Małecka-Panas; Wanda M Krajewska; Piotr Kościelniak; Alexandros Makriyannis; Martin A Storr Journal: PLoS One Date: 2013-12-27 Impact factor: 3.240
Authors: Melissa Ellermann; Alline R Pacheco; Angel G Jimenez; Regan M Russell; Santiago Cuesta; Aman Kumar; Wenhan Zhu; Gonçalo Vale; Sarah A Martin; Prithvi Raj; Jeffrey G McDonald; Sebastian E Winter; Vanessa Sperandio Journal: Cell Date: 2020-10-07 Impact factor: 41.582
Authors: Carina Hasenoehrl; David Feuersinger; Eva M Sturm; Thomas Bärnthaler; Ellen Heitzer; Ricarda Graf; Magdalena Grill; Martin Pichler; Stephan Beck; Lee Butcher; Dominique Thomas; Nerea Ferreirós; Rufina Schuligoi; Caroline Schweiger; Johannes Haybaeck; Rudolf Schicho Journal: Int J Cancer Date: 2017-09-21 Impact factor: 7.396